Cyprium Therapeutics’ CUTX-101 gets FDA fast track designation to treat classic Menkes disease

This article was originally published here

Fortress Biotech announced that the US Food and Drug Administration (FDA) has granted fast track designation to Cyprium Therapeutics Copper Histidinate, also referred to as CUTX-101, for patients diagnosed with classic Menkes disease who have not demonstrated significant clinical progression.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply